PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer

Chen,Rujun; Sheng,Chan; Ma,Ruyue; Zhang,Liwen; Yang,Lina; Chen,Yaping

doi:10.3892/mmr.2021.12440

PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer

Authors:
- Rujun Chen
- Chan Sheng
- Ruyue Ma
- Liwen Zhang
- Lina Yang
- Yaping Chen
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, P.R. China
Published online on: September 14, 2021 https://doi.org/10.3892/mmr.2021.12440
Article Number: 800
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Placenta‑specific protein 1 (PLAC1) is inversely associated with survival in several types of cancer. However, whether PLAC1 is involved in the progression of cervical cancer (CC) remains to be elucidated. Therefore, the present study aimed to evaluate the prognostic role of PLAC1 in CC by determining the relationship between clinicopathological factors, PLAC1 gene expression and survival prognosis using univariate and multivariate Cox proportional‑hazards regression analyses. Similarly, Kaplan‑Meier curves were evaluated with the log‑rank test. Subsequently, gene set enrichment analysis was performed to compare the high‑ and low‑PLAC1 expression phenotypes. Functional studies were further conducted in PLAC1‑overexpressing HeLa cells and PLAC1‑silenced MS751 cells, and western blotting was performed to determine whether PLAC1 promoted CC progression via epithelial‑mesenchymal transition (EMT). The findings demonstrated that high expression of PLAC1 was associated with American Joint Committee on Cancer metastasis pathological score and suggested a poor overall survival. ‘mTOR complex 1 signaling’, ‘interferon α response’ and ‘hypoxia’ were differentially enriched in the high‑PLAC1 phenotype. Furthermore, PLAC1 promoted the invasion of CC cells in vitro. E‑cadherin expression was decreased in the PLAC1‑overexpressing cells, accompanied by increased expression of the mesenchymal markers, Vimentin, MMP2 and Slug, and the opposite effects were observed in PLAC1‑silenced cells. Taken together, the present results indicated that high expression of PLAC1 was associated with poor survival and PLAC1 promoted metastasis via EMT in CC.

View Figures

View References

1	Ferlay JEM, Lam F, Colombet M, Mery L, Piñeros M, Znaora, Soerjomataram I and Bray F: Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; Lyon, France: 2020
2	Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
3	Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, Gao C, Ma D and Liao S: Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 471:88–102. 2020. View Article : Google Scholar : PubMed/NCBI
4	Hermyt E, Zmarzły N, Grabarek B, Kruszniewska-Rajs C, Gola J, Jęda-Golonka A, Szczepanek K, Mazurek U and Witek A: Interplay between miRNAs and Genes Associated with Cell Proliferation in Endometrial Cancer. Int J Mol Sci. 20:E60112019. View Article : Google Scholar
5	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
6	Cocchia M, Huber R, Pantano S, Chen EY, Ma P, Forabosco A, Ko MS and Schlessinger D: PLAC1, an Xq26 gene with placenta-specific expression. Genomics. 68:305–312. 2000. View Article : Google Scholar : PubMed/NCBI
7	Fant ME, Fuentes J, Kong X and Jackman S: The nexus of prematurity, birth defects, and intrauterine growth restriction: A role for plac1-regulated pathways. Front Pediatr. 2:82014. View Article : Google Scholar : PubMed/NCBI
8	Wang X, Baddoo MC and Yin Q: The placental specific gene, PLAC1, is induced by the Epstein-Barr virus and is expressed in human tumor cells. Virol J. 11:1072014. View Article : Google Scholar : PubMed/NCBI
9	Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C and Türeci O: A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res. 67:9528–9534. 2007. View Article : Google Scholar : PubMed/NCBI
10	Devor EJ: Placenta-specific protein 1 (PLAC1) is a unique onco-fetal-placental protein and an underappreciated therapeutic target in cancer(J). Integr Cancer Sci Ther. 3:479–483. 2016. View Article : Google Scholar
11	Dong XY, Peng JR, Ye YJ, Chen HS, Zhang LJ, Pang XW, Li Y, Zhang Y, Wang S, Fant ME, et al: Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. Int J Cancer. 122:2038–2043. 2008. View Article : Google Scholar : PubMed/NCBI
12	Chen J, Pang XW, Liu FF, Dong XY, Wang HC, Wang S, Zhang Y and Chen WF: PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients. Beijing Da Xue Xue Bao. 38:124–127. 2006.PubMed/NCBI
13	Devor EJ, Reyes HD, Gonzalez-Bosquet J, Warrier A, Kenzie SA, Ibik NV, Miller MD, Schickling BM, Goodheart MJ, Thiel KW, et al: Placenta-specific protein 1 expression in human papillomavirus 16/18-positive cervical cancers is associated with tumor histology. Int J Gynecol Cancer. 27:784–790. 2017. View Article : Google Scholar : PubMed/NCBI
14	Jackman SM, Kong X and Fant ME: Plac1 (placenta-specific 1) is essential for normal placental and embryonic development. Mol Reprod Dev. 79:564–572. 2012. View Article : Google Scholar : PubMed/NCBI
15	Old LJ: Cancer is a somatic cell pregnancy. Cancer Immun. 7:192007.PubMed/NCBI
16	Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al: The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 15:5323–5337. 2009. View Article : Google Scholar : PubMed/NCBI
17	GDC Data User's Guide(EB/OL): (2021.08.19), . https://docs.gdc.cancer.gov/Data/PDF/Data_UG.pdf
18	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
19	Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP and Tamayo P: The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
20	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
21	R Core Team R, . A Language And Environment For Statistical Computing. R Foundation For Statistical Computing; Vienna: 2018
22	Goel MK, Khanna P and Kishore J: Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 1:274–278. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, et al: Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun. 11:53322020. View Article : Google Scholar : PubMed/NCBI
24	Mittal V: Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018. View Article : Google Scholar : PubMed/NCBI
25	Goossens S, Vandamme N, Van Vlierberghe P and Berx G: EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 1868:584–591. 2017. View Article : Google Scholar : PubMed/NCBI
26	Liu F, Shen D, Kang X, Zhang C and Song Q: New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma. J Clin Pathol. 68:913–916. 2015. View Article : Google Scholar : PubMed/NCBI
27	Wu Y, Lin X, Di X, Chen Y, Zhao H and Wang X: Oncogenic function of Plac1 on the proliferation and metastasis in hepatocellular carcinoma cells. Oncol Rep. 37:465–473. 2017. View Article : Google Scholar : PubMed/NCBI
28	Liu FF, Dong XY, Pang XW, Xing Q, Wang HC, Zhang HG, Li Y, Yin YH, Fant M, Ye YJ, et al: The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients. Gastroenterology. 134:998–1006. 2008. View Article : Google Scholar : PubMed/NCBI
29	Tchabo NE, Mhawech-Fauceglia P, Caballero OL, Villella J, Beck AF, Miliotto AJ, Liao J, Andrews C, Lele S, Old LJ, et al: Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun. 9:62009.PubMed/NCBI
30	Devor EJ and Leslie KK: The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines. Obstet Gynecol Int. 2013:8078492013. View Article : Google Scholar : PubMed/NCBI
31	Ghods R, Ghahremani MH, Madjd Z, Asgari M, Abolhasani M, Tavasoli S, Mahmoudi AR, Darzi M, Pasalar P, Jeddi-Tehrani M, et al: High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. Cancer Immunol Immunother. 63:1319–1327. 2014. View Article : Google Scholar : PubMed/NCBI
32	Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012. View Article : Google Scholar : PubMed/NCBI
33	Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
34	Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA and Nagle RB: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
35	Wang L, Chang L, Li Z, Gao Q, Cai D, Tian Y, Zeng L and Li M: miR-99a and −99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway. Med Oncol. 31:9342014. View Article : Google Scholar : PubMed/NCBI
36	Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW and Schwarz JK: AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS One. 9:e929482014. View Article : Google Scholar : PubMed/NCBI
37	Kirkwood J: Cancer immunotherapy: The interferon-alpha experience. Semin Oncol. 29:18–26. 2002. View Article : Google Scholar : PubMed/NCBI
38	Kretzmann NA, Chiela E, Matte U, Marroni N and Marroni CA: N-acetylcysteine improves antitumoural response of Interferon alpha by NF-κB downregulation in liver cancer cells. Comp Hepatol. 11:42012. View Article : Google Scholar : PubMed/NCBI
39	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
40	Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 12:122–127. 2006. View Article : Google Scholar : PubMed/NCBI
41	Wilson WR and Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
42	Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P and Vaupel P: Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int J Gynecol Cancer. 11:137–142. 2001. View Article : Google Scholar : PubMed/NCBI
43	Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, Furth EE, et al: EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell. 45:681–695.e4. 2018. View Article : Google Scholar : PubMed/NCBI
44	Wong SHM, Fang CM, Chuah LH, Leong CO and Ngai SC: E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 121:11–22. 2018. View Article : Google Scholar : PubMed/NCBI
45	Lee JY and Kong G: Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression. Cell Mol Life Sci. 73:4643–4660. 2016. View Article : Google Scholar : PubMed/NCBI